Patents Assigned to ISIS Pharmaceuticals Inc.
  • TETRAHYDROPYRAN NUCLEIC ACID ANALOGS
    Publication number: 20130211064
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: April 17, 2013
    Publication date: August 15, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • 2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES
    Publication number: 20130203836
    Abstract: The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Application
    Filed: March 31, 2011
    Publication date: August 8, 2013
    Applicants: ISIS PHARMACEUTICALS, INC., ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Muthiah Manoharan, Eric E. Swayze, Thazha P. Prakash
  • Chimeric oligomeric compounds for modulation of splicing
    Patent number: 8501703
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 6, 2013
    Assignees: Isis Pharmaceuticals, Inc., Sarepta Therapeutics
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard Kole, Casey C. Kopczynski
  • Substituted alpha-L-bicyclic nucleosides
    Patent number: 8501805
    Abstract: The present disclosure describes substituted ?-L-bicyclic nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, substituted ?-L-bicyclic nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: August 6, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze
  • OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE
    Publication number: 20130197062
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: March 21, 2013
    Publication date: August 1, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
    Publication number: 20130189782
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: December 7, 2012
    Publication date: July 25, 2013
    Applicants: CHDI Foundation Inc., Isis Pharmaceuticals, Inc.
    Inventors: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.
  • MODULATION OF FACTOR 11 EXPRESSION
    Publication number: 20130190384
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: December 4, 2012
    Publication date: July 25, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • Antisense modulation of fibroblast growth factor receptor 4 expression
    Patent number: 8486904
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: July 16, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Xing-Xian Yu, Susan M. Freier, Ravi Jain
  • MODULATION OF EIF4E EXPRESSION
    Publication number: 20130178513
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 11, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: ISIS PHARMACEUTICALS, INC.
  • Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
    Patent number: 8481712
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: July 9, 2013
    Assignees: Merck Sharp & Dohme Corp., ISIS Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
  • Modulation of stat5 expression
    Patent number: 8476421
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: July 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, James G. Karras
  • COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR
    Publication number: 20130165496
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: October 26, 2012
    Publication date: June 27, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS
    Publication number: 20130164844
    Abstract: The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.
    Type: Application
    Filed: October 23, 2012
    Publication date: June 27, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • Antisense modulation of kinesin-like 1 expression
    Patent number: 8470795
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: June 25, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller
  • LIPID FORMULATED SINGLE STRANDED RNA
    Publication number: 20130156845
    Abstract: The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: April 29, 2011
    Publication date: June 20, 2013
    Applicants: ALNYLAM PHARMACEUTICALS, INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Sayda Elbashir, Kallanthottathil G. Rajeev, Thazha P. Prakash, Walter F. Lima, Eric E. Swayze
  • BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20130150569
    Abstract: The present invention provides novel 3?,5?-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.
    Type: Application
    Filed: June 6, 2011
    Publication date: June 13, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze, Stephen Hanessian, Benjamin R. Schroeder
  • ANTISENSE MODULATION OF GCCR EXPRESSION
    Publication number: 20130150425
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Application
    Filed: October 25, 2012
    Publication date: June 13, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • ANTIBACTERIAL 4,6-SUBSTITUTED 6', 6'' AND 1 MODIFIED AMINOGLYCOSIDE ANALOGS
    Publication number: 20130144044
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: January 15, 2013
    Publication date: June 6, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: ISIS PHARMACEUTICALS, INC.
  • MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION
    Publication number: 20130143943
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided.
    Type: Application
    Filed: October 12, 2012
    Publication date: June 6, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • Compositions and their uses directed to diacylglycerol acyltransferase 1
    Patent number: 8455456
    Abstract: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: June 4, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Xing-Xian Yu, Sanjay Bhanot, Brett P. Monia